

**CLAIM AMENDMENTS**

Claims 1 – 87 (Canceled).

Claim 88. (currently amended) An isolated antibody or fragment thereof that specifically binds to a protein having at least 90% homology to SEQ ID NO: 728.

Claim 89. (original) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof is a monoclonal antibody.

Claim 90. (original) The antibody or fragment thereof of claim 89, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

Claim 91. (original) The antibody or fragment thereof of claim 88, wherein the fragment is an Fab, F(ab')2, Fv or sFv fragment.

Claim 92. (original) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof is conjugated to an agent.

Claim 93. (original) The antibody or fragment thereof of claim 92, wherein the agent is a diagnostic agent or a cytotoxic agent.

Claim 94. (original) The antibody or fragment thereof of claim 93, wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.

Claim 95. (original) The antibody or fragment thereof of claim 94, wherein the radioactive isotope is selected from the group consisting of  $^{211}\text{At}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{212}\text{Bi}$ ,  $^{32}\text{P}$  and radioactive isotopes of Lu.

Claim 96. (original) The antibody or fragment thereof of claim 94, wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.

Claim 97. (original) The antibody or fragment thereof of claim 94, wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.

Claim 98. (original) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof further comprises a pharmaceutically acceptable carrier.